Elutia Inc. ELUT
- Market cap
- $36.8M
- P/E
- 0.7×
Follow ELUT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 10.55 | 4.10 | 3.37 | 1.10 | 2.16 | 0.50 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 18.00 | 18.20 | 9.01 | 5.38 | 5.24 | 3.80 |
High Price
|
|||
| — | — | — | 151 | 163 | 176 | 164 | 54 | 51 | 26 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 39 | 43 | 43 | 47 | 24 | 25 | 14 | 12 |
Revenue
|
|||
| — | — | 40.84% | 46.08% | 48.17% | 40.14% | 48.80% | 44.67% | 46.42% | 53.66% |
Gross Margin
|
|||
| — | — | (12) | (12) | (22) | (25) | (36) | (41) | (45) | (16) |
EBT
|
|||
| — | — | (29.56%) | (27.76%) | (51.07%) | (52.28%) | (151.57%) | (166.58%) | (313.39%) | (129.00%) |
EBT Margin
|
|||
| — | 0 | (12) | (12) | (22) | (25) | (33) | (38) | (54) | 53 |
Net Income
|
|||
| — | — | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
Depreciation
|
|||
| — | — | 62.01 | 66.41 | 14.96 | 4.54 | 1.72 | 1.36 | 0.50 | 0.30 |
Revenue/Sh
|
|||
| — | — | (18.37) | (18.48) | (8.88) | (2.38) | (2.38) | (2.07) | (1.86) | 1.29 |
Earnings/Sh
|
|||
| — | — | (8.65) | (11.18) | (4.78) | (1.48) | (1.55) | (1.20) | (0.78) | (1.08) |
Cash Flow/Sh
|
|||
| — | — | (0.30) | (0.89) | (0.22) | (0.04) | (0.04) | (0.02) | (0.02) | (0.05) |
Capex/Sh
|
|||
| — | — | (8.95) | (12.08) | (5.00) | (1.51) | (1.59) | (1.22) | (0.80) | (1.13) |
Free CF/Sh
|
|||
| — | — | (68.95) | (85.31) | 7.30 | 1.29 | (0.36) | (2.13) | (1.59) | 0.67 |
Book Value/Sh
|
|||
| — | — | 1 | 1 | 3 | 10 | 14 | 18 | 29 | 41 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 |
PE Ratio
|
|||
| — | — | 0.00 | 0.00 | 3.00 | 1.39 | 2.34 | 1.83 | 7.52 | 2.32 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 6.15 | 4.87 | 0.00 | 0.00 | 0.00 | 1.03 |
PB Ratio
|
|||
| — | — | 0.00 | 0.00 | 2.64 | 1.14 | 3.18 | 2.01 | 8.25 | 1.49 |
EV/Sales
|
|||
| — | — | (7.00) | (7.00) | (7.89) | (3.40) | (3.45) | (2.25) | (5.12) | (0.39) |
EV/FCF
|
|||
| — | — | (5) | (7) | (14) | (15) | (21) | (22) | (23) | (45) |
Op' Cash Flow
|
|||
| — | — | 0 | (1) | (1) | 0 | (1) | 0 | (1) | (2) |
Capex
|
|||
| — | — | (6) | (8) | (14) | (16) | (22) | (22) | (23) | (47) |
FCF
|
|||
| — | — | 5 | 0 | 33 | 21 | 8 | (12) | (12) | 31 |
Working Cap'
|
|||
| — | — | 18 | 21 | 24 | 18 | 37 | 24 | 24 | — |
Total Debt
|
|||
| — | — | 15 | 19 | (15) | (12) | 20 | 4 | 11 | (36) |
Net Debt
|
|||
| — | — | (43) | (55) | 21 | 14 | (5) | (39) | (46) | 28 |
Sh' Equity
|
|||
| — | — | (48.45%) | (25.81%) | (39.72%) | (33.11%) | (48.37%) | (67.08%) | (135.63%) | 108.41% |
ROA
|
|||
| — | — | 0.00% | 0.00% | (156.82%) | (921.57%) | (146.02%) | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | 23.48% | 24.24% | 147.81% | (144.57%) | (775.14%) | 172.60% | 127.15% | (574.35%) |
ROE
|
|||
Elutia Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QTI QT Imaging Holdings, Inc. | $37.0M | 0.0× | Compare |
| ITOC iTonic Holdings Ltd. | $35.4M | — | Compare |
| BDMD Baird Medical Investment Holdings Limited | $32.9M | 0.0× | Compare |
| NSPR InspireMD, Inc. | $32.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SNWV Sanuwave Health Inc. | $41.7M | 3.0× | Compare |
| NSYS Nortech Systems Incorporated | $32.1M | 30.5× | Compare |
| PAVM PAVmed Inc. | $31.0M | 0.0× | Compare |
| TLIS Talis Biomedical Corporation | $46.3M | 0.0× | Compare |
Elutia Inc. (ELUT) key facts
- Elutia Inc. (ELUT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, ELUT traded at $0.82, a market capitalization of $36.8 million.
- Return on equity was −574.4% and debt-to-equity 0.00.
Elutia Inc. (ELUT) Latest News
20 Aug
Elutia Inc. released its Q2 2026 earnings call transcript covering financial results, operations, and outlook. Earnings transcripts deliver financial metrics that can sway near-term investor sentiment and valuation.
18 Aug
Cellution Biologics completes acquisition of SimpliDerm from Elutia Inc. Divestiture of SimpliDerm removes a branded product line from Elutia and shifts its revenue base.
Elutia Inc. completed the SimpliDerm® sale on schedule, adding $8 million in cash proceeds to support NXT-41x advancement through full commercial launch. The completed asset sale supplies immediate capital to execute the NXT-41x commercial launch, a core growth initiative that can materially shift revenue trajectory and investor positioning.
14 Aug
Elutia Inc pivots strategically to NXT41X, delivering strong Q2 2026 earnings performance. Strategic pivot to NXT41X represents major move likely to significantly alter company trajectory and investor sentiment.
Elutia Inc. held its Q2 2026 earnings call covering financial results and outlook. Quarterly earnings updates deliver financial metrics that moderately shape near-term stock movement.
13 Aug
Elutia Inc. secured up to $26 million to fund NXT-41x through commercial launch and reported second quarter 2026 results. Up to $26 million funding enables NXT-41x commercialization and supports major growth trajectory for Elutia.
Elutia secures $15 million loan financing from Avenue Capital Group to fund NXT-41x launch in $1.5 billion plastic and reconstructive surgery market. Securing $15 million financing enables launch of NXT-41x product targeting large market.
16 Jul
Cellution Biologics Inc. signed a definitive agreement to acquire Elutia Inc.'s SimpliDerm human hydrated acellular dermal matrix business, expanding Cellution's allograft portfolio. Divestiture of the SimpliDerm business removes a core product line and directly changes Elutia's revenue base and strategic direction.
Elutia signs definitive agreement to sell SimpliDerm in transaction valued at up to $11 million, strengthening balance sheet ahead of NXT-41x launch. Sale of SimpliDerm for up to $11 million strengthens Elutia's balance sheet ahead of NXT-41x launch, positioning for potential growth.
15 May
Elutia (ELUT) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 earnings transcripts disclose key financial metrics, strategic updates, and outlook that significantly sway investor sentiment and stock trajectory.
Elutia Inc. held its Q1 2026 earnings call and reported financial results along with operational updates and forward guidance. Quarterly earnings data and guidance typically produce moderate short-term effects on share price and sentiment without guaranteed long-term structural change.
Elutia Inc. (ELUT) Q1 2026 earnings call highlights strategic advances amid revenue shifts. Strategic advances balance revenue shifts, moderately impacting financial performance and trajectory.
14 May
Elutia Inc. reported first quarter 2026 financial results and highlighted NXT-41x progress toward the $1.5 billion U.S. plastic and reconstructive surgery market. Quarterly results and NXT-41x advances target a $1.5B market, signaling significant strategic growth potential.
11 Mar
Elutia Inc. (ELUT) Q4 2025 earnings call highlights revenue growth and strategic moves amid challenges. Revenue growth and strategic moves represent major positive developments likely to boost investor sentiment and alter company trajectory.
Elutia Inc. Q4 2025 earnings call summary covers financial results, operational highlights, and forward guidance for the biomaterials company. Q4 earnings summaries detail revenue, profitability, and strategic outlook directly impacting investor confidence and stock valuation.
Elutia Inc. (ELUT) released the transcript of its Q4 2025 earnings call, detailing financial results, operational updates, and future outlook. Q4 earnings call transcript discloses year-end financials, guidance, and strategic plans that can significantly sway investor sentiment and stock trajectory.
Elutia Inc. reported fourth quarter and full-year 2025 financial results and initiated the regulatory process for NXT-41. Financial results reporting combined with NXT-41 regulatory initiation marks major strategic and pipeline advancements impacting future performance.
4 Mar
Elutia Inc. (ELUT) regains compliance with Nasdaq listing requirements after addressing prior deficiencies. Regaining Nasdaq compliance averts delisting risk and enhances stock visibility and investor confidence.
2 Mar
Elutia Inc. (ELUT) appoints Pete Ligotti as Chief Commercial Officer to lead the commercial launch of NXT-41x, aiming to transform post-mastectomy care in the $1.5 billion U.S. breast surgery market. Appointing a CCO to lead NXT-41x launch targets a $1.5B market, enabling major commercial expansion and revenue growth.
4 Feb
An insider at Elutia Inc. (ELUT) has purchased additional shares worth US$74,000, indicating confidence in the company's future performance. This transaction reflects a commitment to the company's growth and may influence investor sentiment positively. Insider buying can signal confidence in the company's prospects, potentially affecting market sentiment and stock performance.
12 Jan
Elutia Inc. reported preliminary results for the fourth quarter of 2025, highlighting a strengthened financial position. The company anticipates significant milestones related to its NXT-41x product, which could influence future growth and market performance. Upcoming NXT-41x milestones are expected to significantly impact the company's trajectory and investor sentiment.
9 Jan
Elutia Inc. will present its NXT-41x Biomatrix Program at the Global BioInnovation Forum, focusing on advancements in plastic and reconstructive surgery. This program aims to enhance surgical outcomes and patient recovery through innovative biomaterials. The presentation highlights Elutia's commitment to addressing unmet needs in the medical field and showcases its potential contributions to the industry. The presentation of the NXT-41x Biomatrix Program could significantly influence Elutia's market positioning and investor sentiment in the medical technology sector.
31 Dec
Elutia Inc. (ELUT) has been upgraded to a 'Buy' rating by analysts, reflecting positive sentiment regarding the company's growth potential and market position. This upgrade is based on recent developments that suggest improved financial performance and strategic initiatives aimed at enhancing product offerings. Investors are encouraged to consider this upgrade as a signal of confidence in Elutia's future prospects. The upgrade to 'Buy' indicates significant confidence in Elutia's strategic direction and potential for improved market performance.
2 Dec
Elutia Inc. has announced the sale of its BioEnvelope technology, a strategic move aimed at reshaping its business model and enhancing future valuation. This sale is expected to provide the company with additional capital and refocus its efforts on core operations, potentially leading to improved financial performance and market positioning. The transaction marks a significant shift in Elutia's strategy, indicating a commitment to innovation and growth in its primary areas of expertise. The sale of the BioEnvelope technology is a major strategic move that could significantly alter Elutia's trajectory and investor sentiment.
Boston Scientific's M&A strategy is expected to enhance its growth prospects, particularly through the acquisition of Elutia Inc. (ELUT). This move aims to strengthen Boston Scientific's position in the medical device market, leveraging Elutia's innovative technologies and expanding its product offerings. The integration is anticipated to drive revenue growth and improve competitive advantages in the industry. The acquisition of Elutia Inc. is likely to significantly impact Boston Scientific's growth trajectory and market positioning.
17 Nov
Elutia Inc. has recently sold its BioEnvelope technology, prompting analysts to reassess the company's future prospects. The sale is seen as a strategic move that could allow Elutia to focus on its core operations and enhance its financial position. Analysts believe this shift may lead to improved market sentiment and potential growth opportunities for the company, as it reallocates resources and capital towards more promising ventures. The sale of BioEnvelope is a significant strategic move that could alter Elutia's trajectory and investor sentiment.
7 Nov
Elutia Inc. released Q3 2025 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q3 earnings call summary reveals key financial metrics and strategic updates that significantly shape investor expectations and stock trajectory.
Elutia Inc. (ELUT) reported strong Q3 2025 earnings, highlighting strategic growth initiatives and financial resilience. The company emphasized its commitment to innovation and expanding market presence, which contributed to improved revenue and profitability metrics. Management outlined plans for future investments and operational efficiencies aimed at sustaining growth momentum. Overall, the earnings call reflected a positive outlook for Elutia's performance in the coming quarters. Significant strategic growth initiatives and financial resilience are likely to impact future performance and investor sentiment.
6 Nov
Elutia Inc. reported its third quarter 2025 financial results and announced the completion of an $88 million sale of its BioEnvelope business to Boston Scientific Corporation. The proceeds from this sale will be used to fund the development of NXT-41x. The sale of the BioEnvelope business and the funding for NXT-41x represent significant strategic moves that could alter Elutia's future trajectory and market position.
2 Nov
Elutia Inc. is undergoing a strategic refocus following the sale of its BioEnvelope division, prompting analysts to reassess their outlook on the company. The sale is expected to streamline operations and enhance focus on core competencies, potentially leading to improved financial performance and market positioning. Analysts are adjusting their ratings and price targets in light of these developments, indicating a shift in sentiment towards the company's future prospects. The sale of the BioEnvelope division is expected to moderately influence Elutia's financial performance and strategic focus.